<DOC>
	<DOC>NCT00004268</DOC>
	<brief_summary>OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen.</brief_summary>
	<brief_title>Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a partially randomized, multicenter study. Patients receive oral midodrine three times a day during weeks 1 and 3-5, then either oral midodrine or placebo for weeks 6-8. Quality of life is assessed at weeks 3, 6, and 8.</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Hypotension, Orthostatic</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Orthostatic hypotension due to autonomic nervous system failure, i.e.: Fall in systolic blood pressure (supine to standing) of at least 15 mm Hg AND Symptoms of dizziness, lightheadedness, unsteadiness with a severity of 4.5 or less on a 10 point scale in 2 of 3 evaluations over a 3 day period Prior/Concurrent Therapy No concurrent sympathomimetics or alphareceptor agonists or antagonists No concurrent drug with significant smooth muscle relaxant or constrictive properties e.g., calcium channel blockers At least 30 days since other prior investigational agents Patient Characteristics Hepatic: No coagulopathy Renal: No acute nephritis or chronic renal failure Cardiovascular: No sustained supine hypertension greater than 180/110 mm Hg No congestive heart failure No myocardial infarction within the last 6 months No uncontrolled arrhythmia (ventricular tachycardia or second or third degree heart block not treated with pacemaker) No unstable angina pectoris No history of cerebral vascular accident Other: No pheochromocytoma No thyrotoxicosis No seizure disorder Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>cardiovascular and respiratory diseases</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>orthostatic hypotension</keyword>
	<keyword>quality of life</keyword>
	<keyword>rare disease</keyword>
</DOC>